OMERS ADMINISTRATION Corp Trims Position in Climb Bio, Inc. $CLYM

OMERS ADMINISTRATION Corp decreased its position in shares of Climb Bio, Inc. (NASDAQ:CLYM) by 80.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,700 shares of the company’s stock after selling 68,766 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Climb Bio were worth $114,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of CLYM. Seven Fleet Capital Management LP acquired a new stake in Climb Bio during the fourth quarter worth about $306,000. ArchPoint Investors acquired a new position in Climb Bio in the 4th quarter valued at about $486,000. 683 Capital Management LLC acquired a new position in Climb Bio in the 4th quarter valued at about $807,000. Peapod Lane Capital LLC boosted its holdings in Climb Bio by 0.7% in the 4th quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock valued at $2,264,000 after purchasing an additional 4,126 shares during the last quarter. Finally, Hsbc Holdings PLC grew its stake in shares of Climb Bio by 107.2% in the 4th quarter. Hsbc Holdings PLC now owns 24,744 shares of the company’s stock valued at $99,000 after buying an additional 12,800 shares during the period. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Climb Bio Price Performance

NASDAQ CLYM opened at $11.90 on Friday. The stock has a market capitalization of $681.39 million, a P/E ratio of -15.26 and a beta of 0.07. The firm’s 50-day moving average is $12.20 and its two-hundred day moving average is $8.99. Climb Bio, Inc. has a 12 month low of $1.36 and a 12 month high of $14.41.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. As a group, analysts anticipate that Climb Bio, Inc. will post -0.87 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on CLYM. Wall Street Zen upgraded shares of Climb Bio from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Chardan Capital initiated coverage on Climb Bio in a report on Tuesday, May 5th. They issued a “buy” rating and a $22.00 price objective on the stock. BTIG Research increased their price objective on Climb Bio from $19.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, June 11th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Climb Bio in a research report on Wednesday, June 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $22.00.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.